Benzodiazepines: Risks and Options

A Guide for Patients and Prescribers

Cara T. Hoepner, MS, RN, CS, PMHNP-BC — March 2026

At a Glance

What Benzodiazepines Do

Benzodiazepines enhance GABA, the brain's calming neurotransmitter. They work within 20–30 minutes to reduce anxiety, stop panic, relax muscles, and promote sleep. Common examples: alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium).

Key Reasons to Be Cautious

- **Cognitive Impact:** 1,000+ peer-reviewed studies document impaired memory, attention, and multitasking. [1] Benzos may interfere with psychotherapy by blunting emotional processing and fear extinction. [2,3]
- **Physical Dependence:** Tolerance and dependence can develop within days to weeks. Withdrawal can be prolonged, lasting months.
- **Falls and Mortality:** In older adults, fall risk increases 20–50% [4] and hip fractures 50–110%. [5] Even low doses are associated with doubled all-cause mortality and potential cancer links with long-term use.
- **Trauma Healing:** Memory formation is central to trauma recovery; [6] benzos can undermine PTSD treatment.

Main Non-Benzo Options

For Anxiety:

- Gabapentin/pregabalin—effective for anxiety with physical symptoms [7,8]
- Propranolol—performance anxiety, test-taking [9]
- Clonidine—hyperadrenergic symptoms: racing heart, sweating, startle [10]
- SSRIs/SNRIs—first-line in many practices (I do not use them; handout available on request)
- Supplements: niacinamide, [11] glycine, [12,13] L-theanine, [14] GABA [15]

For Sleep:

- Trazodone (initiation) [16]
- Gabapentin (maintenance/quality) [17]

- Mirtazapine (initiation, maintenance, quality) [18]
- Orexin antagonists: Belsomra, Quviviq, Dayvigo [19]
- Sleep hygiene and behavioral practices

Behavioral:

- Paced breathing, [20,21] meditation, [22,23] grounding [24]
- Trauma-informed psychotherapies; limbic system retraining

A Word of Validation

If you are currently taking a benzodiazepine, that does not mean you or your prescriber did anything wrong. For many people, benzos were the best available option at the time. This guide helps you understand benefits and risks so you can make informed decisions going forward.

How This Guide is Organized

Sections cover: mechanism of action, short-term benefits, side effects/risks (cognitive, sleep, mortality, cancer), special populations, withdrawal/tapering, resources, alternatives, and questions for your prescriber. Focus on what's relevant to you.

What Benzodiazepines Are and How They Work

Benzodiazepines are CNS depressants that enhance GABA, the brain's main inhibitory neurotransmitter. GABA acts like a brake—when it binds its receptors, neurons fire less, producing calming and sedating effects. [25] Benzos bind GABA-A receptors and amplify GABA's effect, explaining their rapid onset. [25,26]

Key distinctions: [27]

- **Short-acting** (alprazolam, lorazepam): Quick onset, wear off in hours, can cause interdose withdrawal
- **Intermediate-acting** (clonazepam): Longer, steadier coverage
- **Long-acting** (diazepam): Half-lives of a day or more, more stable blood levels

Benzos also have muscle-relaxant, anticonvulsant, and amnesia-producing properties. The same mechanisms that make them acutely effective—rapid onset, strong anxiolytic effects—also drive tolerance, dependence, and cognitive impairment with chronic use.

Short-Term Benefits

In acute distress—panic attacks, severe anxiety, insomnia—benzodiazepines provide rapid

relief (20–30 minutes). For panic disorder, having a benzo available can itself reduce anticipatory anxiety. In medical settings, they're valuable for procedures, acute alcohol withdrawal, seizures, and muscle spasms.

Short-term use (days to weeks) carries lower risk. The problem: "short-term" often becomes long-term because benzos work well and the conditions they treat are chronic. Tolerance develops within weeks; psychological and physical dependence can form even with as-prescribed use. What began as relief can shift to needing the medication to feel "normal." This is not moral failing—it is predictable neurobiology.

Side Effects and Risks

Cognitive Deficits

More than 1,000 peer-reviewed papers document cognitive risks:

- **Attention/Multitasking:** Slowed reactions, increased mistakes—not just driving but cooking, finances, complex instructions [1]
- **Facial Recognition:** Impaired ability to read expressions, especially anger, causing relationship difficulties [28]
- **Memory:** Impaired new learning, processing speed, visuospatial skills [1,29]
- **Synapses and memory:** Long-term daily use over-activates GABA-A receptors in memory-critical regions like the hippocampus, dampening neuroplasticity, reducing dendritic spine density, and weakening long-term potentiation—leading to measurable and sometimes persistent problems with new learning and memory. [1,30,31] In large imaging cohorts, current benzo use is linked to faster hippocampal and amygdala shrinkage. [32] Avoid long-term daily use whenever possible, especially in older adults
- **Psychotherapy Impact:** Emotional numbing and memory impairment make therapy less effective; benzos impair fear extinction needed for exposure therapy [2,3]
- **Trauma healing:** Use sparingly in people with trauma histories or PTSD—effective trauma therapies work by forming new, non-fear memories, and benzos impair fear-memory extinction and exposure-based learning, worsening PTSD outcomes over time [3,33–35]
- **Persistence:** Deficits may persist >6 months after stopping; some may be permanent [36]

Sleep Architecture

Bedtime benzos worsen all cognitive risks. While they may help you fall/stay asleep, they disrupt sleep architecture:

- **REM Sleep:** Compressed, delayed, reduced quality. REM is crucial for learning/memory, [37] cardiovascular health, [38] and emotional processing. [39] The

amygdala is highly active during REM. [40]

- **Slow Wave Sleep:** Reduced delta power. This stage enables glymphatic clearance of waste including amyloid-beta. [41] Microglial inflammation affects BDNF availability, impairing memory. [42–45]
- **Overall Quality:** Increased light (stage 2) sleep, reduced restorative sleep. [46,47] You may sleep longer but wake with fatigue and brain fog.

Dementia Risk

Many papers suggest increased Alzheimer's risk with long-term use, often citing anticholinergic effects. However, a 200,000+ subject study found this may not be true [48]. Notably, benzos don't cause typical anticholinergic side effects. The question remains unsettled.

Safety: Accidents

Benzos significantly increase accident risk with automobiles and machinery due to sedation, slowed reactions, and impaired judgment. [49]

Mortality

A cohort study (n=5,212) found benzo use—with or without opioids—associated with doubled all-cause mortality vs. low-risk antidepressants for anxiety. [50]

Cardiac and Autonomic Harms

Sedative–hypnotics don't just make people sleepy. They can also disturb the heart's rhythm. Zolpidem in particular now has evidence that it can trigger abnormal heart rhythms. At high doses, and in vulnerable people, it can lengthen the heart's electrical "reset" time (the QT interval), which increases the chance of dangerous rhythms, including atrial fibrillation and even rhythm problems that can lead to cardiac arrest. [51] It can also slightly lower oxygen levels at night and nudge the nervous system that controls heart rate and blood pressure, especially in patients with underlying cardiopulmonary disease. [52] Large population studies find that people taking zolpidem have more documented arrhythmias than similar people who do not take it, and the risk goes up the more they use. [53]

This is not only an overdose problem. There are reports of atrial fibrillation and marked QT changes at or near usual doses, especially in people who already have heart disease, low potassium or magnesium, or are taking other QT-prolonging medications. [54,55] In those cases, zolpidem seems to act as the "last straw" on top of an already stressed heart. Because insomnia so often travels with high blood pressure, diabetes, and other cardiac conditions, these are exactly the types of patients who are likely to be offered sleep medications.

The other Z-drugs—eszopiclone and zaleplon—do not yet have the same amount of data, but that should not be read as a clean bill of health. They work on the same receptor system (GABA-A) in slightly different ways; zolpidem is more narrowly targeted, but all of them push on the same basic brake and can deepen nighttime breathing problems and shift autonomic tone in ways that may also provoke rhythm issues in susceptible hearts. [52,56]

When researchers look at hypnotics as a group—benzodiazepines plus Z-drugs—people who use them have significantly higher rates of new-onset atrial fibrillation, and the risk climbs with dose and duration. [56]

This matters because these medicines are most often given to older adults who already have cardiovascular disease, diabetes, or sleep apnea—the very people least able to tolerate extra strain on the heart. For them, a pill offered as a sleep aid can quietly raise the odds of the arrhythmias that lead to stroke, heart failure, or sudden death. [53,56] That trade-off is rarely discussed when a prescription is written, but it deserves to be part of any informed decision about starting a benzodiazepine receptor agonist.

Cancer Risk

Long-term use appears to be a significant cancer risk:

- Representative studies: [57–59]
- Kripke et al. (2012): [60] Even 1–18 pills/year of hypnotics (including benzos and Z-drugs) associated with >3× death risk (HR 3.60, 95% CI 2.92–4.44)
- Iqbal et al. (2015): [61] Diazepam, chlordiazepoxide, medazepam, nitrazepam, oxazepam safer; clonazepam higher cancer risk. Increased risk: brain (98%), colorectal (25%), lung (10%)

Important: These are associations, not proof of causation. Unmeasured factors may contribute. But signals are strong enough to minimize duration/dose.

Functional/Occupational Impacts

- **Work:** Cognitive/psychomotor slowing impairs learning, reduces performance, increases errors [62]
- **Healthcare Workers:** Associated with poorer performance and more mistakes [63]
- **Parenting/Safety-Sensitive Roles:** Raises safety concerns for dependents and public [64]

Special Populations

Older Adults

The American Geriatrics Society lists benzos as “potentially inappropriate.” In this population, benzos may:

- Increase fall risk 20–50% [4]
- Increase hip fracture risk 50–110% [5]
- Cause sedation/daytime sleepiness due to pharmacokinetic changes [65]
- Impair cognition subtly-to-moderately [66]
- Double motor vehicle accident risk [67]

- Increase mortality 1.2–3.7× [68–70]

Depression and Self-Harm

Long-term use, particularly clonazepam, may increase depression [71] and suicidality. [72]

Trauma and PTSD

VA/DoD, APA, NICE, and others recommend against benzos for PTSD—they don't improve core symptoms and may worsen recovery or interfere with trauma therapy. [35,73–75] Long-term use can cause progressive behavioral dyscontrol (irritability, aggression, impulsivity), especially with short-acting agents like alprazolam. [76,77]

Pregnancy and Breastfeeding

- Possible small increase in orofacial cleft risk [78]
- Risk of "floppy infant" or neonatal withdrawal with late-pregnancy/high-dose use [79]
- Sedation in breastfed infants, especially with other CNS depressants [80]

Addiction Potential

Significant addiction potential, particularly alprazolam. [81] People with substance use disorders are especially prone to misuse. [82] Even as-prescribed use: ~1–2% develop use disorder, ~17% report some misuse. [83]

Polysubstance Use

- **Alcohol:** Markedly increased CNS depression, worse mental health outcomes [84]
- **Stimulants:** Signals entrenched polydrug use and greater functional impairment [82,85]
- **Opioids:** May result in respiratory depression and death [86]

If You Are Already Taking a Benzodiazepine

Medicolegal Concerns

Long-term use faces closer scrutiny: PDMPs, duration limits, documentation requirements. [87] New providers may hesitate to continue prescriptions and are expected to re-evaluate indication, review risks/benefits, and discuss deprescribing. Guidelines recommend regular reviews and gradual, individualized tapers—never abrupt discontinuation in dependent patients. [88] Qualitative studies show tighter regulations can leave users feeling abandoned. [89]

Withdrawal

Approximately 15 percent of people endure tapers lasting ≥1 year. Post-acute withdrawal

(PAWS) can last months to years and may include: intense physical/neurological-feeling anxiety, panic attacks, insomnia and fragmented sleep, cognitive impairment ("brain fog"), memory problems, depersonalization/derealization, tinnitus, burning skin sensations, muscle pain and tension, tremors, GI distress, profound fatigue, depression, and emotional blunting. Some people describe it as feeling like their nervous system has been fundamentally destabilized. Symptoms can wax and wane unpredictably, sometimes returning in "waves" long after the taper is complete.

Tapering Approaches:

- Reduce dose by ~10% every 2–4 weeks (from current dose, not original). Adjust slower if needed [87]
- Interdose withdrawal is worse with short-acting benzos (alprazolam, lorazepam). Cross-titration to longer-acting agents often helps [90]
- Some cross-taper to diazepam, then taper off. [15] Avoid in older adults due to long metabolites.
- Fine-tuning: Gram scale for small adjustments; compounded liquid for precise dosing.

Medications That May Assist Tapering:

- **Levetiracetam (Keppra):** Stabilizes GABAergic inhibition. [91] No data for benzo tapers, but I rely on it for this and for stemming tolerance.
- **Pregabalin** [92] **and gabapentin** (lesser degree) [93]
- **Carbamazepine** [94] **and valproate** [92]
- **Oxcarbazepine:** Single study supports use; [95] same active moiety as carbamazepine but more tolerable

Resources for Education and Tapering

Educational/Clinical:

- The Ashton Manual (diazepam-based taper; substitute as needed). PAWS info: here, here
- Oregon Health Authority Tapering Guidelines
- Inner Compass Guide
- Benzodiazepine Information Coalition
- Alliance for Benzodiazepine Best Practices
- VA/DoD Clinician's Guide to PTSD Medications
- Canadian Deprescribing Network

Online Community Support:

- Beating Benzos, Benzodiazepine Recovery, Freedom from Psychiatric Meds
- BenzoBuddies (large peer forum), Benzo Hope (Zoom meetings)
- Benzodiazepine Dangers, Benzo Beware, Benzo Hell & Recovery
- World Benzodiazepine Awareness Day, Christian Withdrawal Support

When Benzodiazepines May Be Appropriate

I consider these medicines put something between the client and the world, attenuating healthy life. I use them judiciously for:

- **Overwhelming circumstances** not responsive to gabapentin/pregabalin and good sleep protocols (temporary)
- **Panic disorder** while awaiting other treatments, or infrequent PRN for attacks
- **Activating antidepressants:** Helping through initial SSRI side effects
- **Night terrors in adults:** Clonazepam for 6 weeks
- **Catatonia:** Lorazepam 1–2 mg IM/IV; 6–20 mg daily. First-line.
- **Neuroleptic malignant syndrome:** Lorazepam 1–2 mg IM/IV q4–6h; taper over 10–14 days
- **Occasional long-term use:** Speeches, flights, BART rides when propranolol doesn't help

---

Alternatives for Anxiety

Gabapentinoids

Excellent for anxiety with physiologic symptoms, [7,8] neuropathic pain, [96] withdrawal syndromes. [92,93] Helpful with trauma history; gabapentin glues sleep together. [17] Watch for sedation and misuse potential in SUD populations.

- **Gabapentin:** Typically 600 mg TID; I've used up to 4,800–5,400 mg/day. Safe at high doses except in renal impairment.
- **Pregabalin:** 50–900 mg in 2–3 divided doses; usually ~150 mg BID. Far surpasses gabapentin for generalized worry.

Clonidine, Guanfacine, Propranolol

Useful for hyperadrenergic activation (tachycardia, sweating, startle). Caution: hypotension and rebound if stopped abruptly.

- **Clonidine** (much more than guanfacine) **for anxiety:** Best when hyperadrenergic symptoms prominent. [10] Both help emotional regulation (guanfacine > clonidine), [97,98] nightmares, [99,100] focus/impulsivity in ADHD. [101,102]
- **Propranolol:** Stage fright, specific social anxiety [9]. Some clients drop their benzo after finding propranolol leaves them clear, sharp, calm. Contraindicated in asthma or bradycardia.
- **Combination strategy for panic:** Clonidine or prazosin + propranolol. No data, but

can be safely established by starting clonidine/prazosin first, then titrating propranolol while monitoring BP. Many panic treatments exist without SSRIs or benzos—full list available on request.

Quetiapine

Effect size 1.3 in GAD trials. [103] May cause weight gain, diabetes; monitor weight, glucose, lipids [104], prolactin. [105] Increases light sleep, decreases REM. [106,107] Risk of movement disorders. [108]

Niacinamide

Facilitates GABA modulation; effects comparable to benzos in some cases despite weak receptor affinity. [11] May raise serotonin via tryptophan sparing. [109] Dose: up to 750 mg 3–4×/day (~2,000–2,500 mg/day); effects typically within 1 week. Nausea/vomiting at ~6,000 mg/day.

Glycine

Modulates excitatory neurotransmission through inhibitory glycine receptors and NMDA glycine site [12,13]. 1–6 g gives relief in ~30 min, lasting ~4 hours.

Amino Acids (GABA and L-Theanine)

- **GABA:** Calming [15]. Available as PharmaGABA (naturally fermented, generally considered more bioavailable) or synthetic GABA. Blends: GABA Calm (Source Naturals), True Calm (NOW Foods).
- **L-Theanine:** Reduces stress [14], improves attention/executive function. [110] 100–400 mg/dose (typically 200 mg). Helps anxious people focus. Suntheanine is a patented, synthetically produced form that is superior to L-theanine sourced from tea leaves—standardized and reliable batch to batch.
- I'm not a fan of blends—ingredients aren't individually dosed.

Alternatives for Sleep

- **Trazodone:** Initiation, promotes slow wave sleep [16]; safe in obstructive sleep apnea (OSA).
- **Gabapentin:** Maintenance and quality [17]
- **Baclofen:** Maintenance, total sleep time, efficiency, slow wave sleep. [111] Anecdotally helps initiation; I prescribe it often.
- **Mirtazapine:** Efficiency, slow wave, REM, reduces wake-after-sleep-onset . [18] Safe in OSA. Weight gain is near-certain—which worsens OSA.
- **Clonidine:** Initiation/maintenance in select populations (RLS; [112] postoperative [113]) – and also safe in OSA.
- **Orexin antagonists** (Belsomra, Quviviq, Dayvigo): Month-over-month improvements in efficiency, latency, wake-after-sleep-onset, total sleep time for full study

year. [19] No tolerance, withdrawal, or rebound; sleep architecture preserved. [114] Anecdotally useful for circadian entrainment and jet lag. Safe in OSA.

Behavioral Supports

- Paced breathing: Increases parasympathetic/vagal activity and HRV [20,21]
- Meditation: Vedic/TM, [22] mindfulness [23]
- Grounding techniques [24]
- Sleep hygiene [115]
- Trauma-informed psychotherapies (ask for list)
- Limbic system retraining (ask for resources)

Questions to Bring to Your Prescriber

1. What are my non-benzodiazepine options?
2. Could we try a slow reduction plan?
3. How will we monitor thinking, balance, and mood?
4. What's the plan for duration?
5. What support is available during tapering?
6. Are there specific risks given my age, history, or other medications?
7. How might this affect my ability to benefit from therapy?
8. What should I watch for indicating problems?
9. What should I do if I need more medication for the same effect?
10. Can we schedule regular check-ins to reassess?

Final Thoughts

Benzodiazepines provide significant short-term relief. For some people in specific circumstances, they remain appropriate. But accumulating evidence on cognitive, physical, and functional risks—especially long-term—requires thoughtful decision-making.

If you're currently taking a benzo, this isn't meant to alarm you. It's meant to inform decisions going forward—continuing, adjusting, tapering, or exploring alternatives—honoring both immediate needs and long-term health.

You deserve collaborative, informed, responsive care. Ask questions, seek second opinions, advocate for what feels right.

Bibliography

1. Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 1;33(7):901–11. doi:10.1093/arclin/acx120 PubMed PMID: 29244060.

2. Curran HV, Bond A, O'Sullivan G, Bruce M, Marks I, Lelliot P, Shine P, Lader M. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. Psychol Med. 1994 Nov;24(4):969–76. doi:10.1017/s0033291700029056 PubMed PMID: 7892364.

3. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, Davis M, Bradley B, Duncan EJ, Rizzo A, Ressler KJ. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry. 2014 Jun;171(6):640–8. doi:10.1176/appi.ajp.2014.13121625 PubMed PMID: 24743802; PubMed Central PMCID: PMC4115813.

4. Capiau A, Huys L, van Poelgeest E, van der Velde N, Petrovic M, Somers A, EuGMS Task, Finish Group on FRIDs. Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review. Eur Geriatr Med. 2023 Aug;14(4):697–708. doi:10.1007/s41999-022-00731-4 PubMed PMID: 36576689; PubMed Central PMCID: PMC10447278.

5. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17(11):825–37. doi:10.2165/00023210-200317110-00004 PubMed PMID: 12921493.

6. Damis LF. The Role of Implicit Memory in the Development and Recovery from Trauma-Related Disorders. NeuroSci. 2022 Mar;3(1):63–88. doi:10.3390/neurosci3010005 PubMed PMID: 39484673; PubMed Central PMCID: PMC11523743.

7. Lavigne JE, Heckler C, Mathews JL, Palesh O, Kirshner JJ, Lord R, Jacobs A, Amos E, Morrow GR, Mustian K. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012 Nov;136(2):479–86. doi:10.1007/s10549-012-2251-x PubMed PMID: 23053645; PubMed Central PMCID: PMC4411951.

8. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010 Mar;13(2):229–41. doi:10.1017/S1461145709990460 PubMed PMID: 19737439.

9. Elsey JWB, Filmer AI, Galvin HR, Kurath JD, Vossoughi L, Thomander LS, Zavodnik M, Kindt M. Reconsolidation-based treatment for fear of public speaking: a systematic pi-

lot study using propranolol. Transl Psychiatry. 2020 Jun 4;10(1):179. doi:10.1038/s41398-020-0857-z PubMed PMID: 32499503; PubMed Central PMCID: PMC7272450.

10. Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry. 1981 Nov;38(11):1278–82. doi:10.1001/archpsyc.1981.01780360094011 PubMed PMID: 7305609.

11. Bold JM, Gardner CR, Walker RJ. Central effects of nicotinamide and inosine which are not mediated through benzodiazepine receptors. Br J Pharmacol. 1985 Mar;84(3):689–96. doi:10.1111/j.1476-5381.1985.tb16151.x PubMed PMID: 2985162; PubMed Central PMCID: PMC1987159.

12. Shishkova VN, Николаевна ШВ, Nartcissov YR, Рюрикович НЯ, Titova VY, Юрьевна ТВ, Sheshegova EV, Викторовна ШЕ. Molecular mechanisms defining application of glycine and zinc combination in correction of stress and anxiety main manifestations. Pharmacy & Pharmacology. 2022 Oct 2;10(5):404–15. doi:10.19163/2307-9266-2022-10-5-404-415

13. Wolosker H, Balu DT. D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders. Transl Psychiatry. 2020 Jun 9;10(1):184. doi:10.1038/s41398-020-00870-x PubMed PMID: 32518273; PubMed Central PMCID: PMC7283225.

14. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007 Jan;74(1):39–45. doi:10.1016/j.biopsycho.2006.06.006 PubMed PMID: 16930802.

15. Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors. 2006;26(3):201–8. doi:10.1002/biof.5520260305 PubMed PMID: 16971751.

16. Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004 Jan;5(1):15–20. doi:10.1016/j.sleep.2003.06.006 PubMed PMID: 14725822.

17. Yeh WC, Lu SR, Wu MN, Lee KW, Chien CF, Fong YO, Li KY, Lai YL, Lin CJ, Li YS, Su CY, Wang YC, Lin YH, Chen TY, Tseng PT, Hsu CY. The impact of antiseizure medications on polysomnographic parameters: a systematic review and meta-analysis. Sleep Med. 2021 May;81:319–26. doi:10.1016/j.sleep.2021.02.056 PubMed PMID: 33756282.

18. Mi WF, Tabarak S, Wang L, Zhang SZ, Lin X, Du LT, Liu Z, Bao YP, Gao XJ, Zhang WH, Wang XQ, Fan TT, Li LZ, Hao XN, Fu Y, Shi Y, Guo LH, Sun HQ, Liu L, Si TM, Zhang HY, Lu L, Li SX. Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional con-

nectivity analyses. Sleep. 2020 Nov 12;43(11):zsaa092. doi:10.1093/sleep/zsaa092 PubMed PMID: 32406918.

19. Xue T, Wu X, Li J, Chen S, Wang Z, Tan X, Wang Z, Zhang J. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis. Front Pharmacol. 2023;14:1175372. doi:10.3389/fphar.2023.1175372 PubMed PMID: 37261282; PubMed Central PMCID: PMC10228643.

20. Goncalvez, Paloma, Rafaly Da Silva Pereira, Ana, Da Motta Sempaio Coelho, Bianca, Aletti, F, Ricardo Asnati. Effects on Heart Rate Variability and Salivary Cortisol of Slow Paced Breathing for Stress Management | Semantic Scholar. In. 2025 [cited 2025 Dec 20]. Available from: https://www.semanticscholar.org/paper/Effects-on-Heart-Rate-Variability-and-Salivary-of-Gon%C3%A7alves-Aletti/870571df8cf116f99c1401898a9ca2e36f03ceb3

21. Magnon V, Dutheil F, Vallet GT. Benefits from one session of deep and slow breathing on vagal tone and anxiety in young and older adults. Sci Rep. 2021 Sep 29;11(1):19267. doi:10.1038/s41598-021-98736-9 PubMed PMID: 34588511; PubMed Central PMCID: PMC8481564.

22. Orme-Johnson DW, Barnes VA. Effects of the transcendental meditation technique on trait anxiety: a meta-analysis of randomized controlled trials. J Altern Complement Med. 2014 May;20(5):330–41. doi:10.1089/acm.2013.0204 PubMed PMID: 24107199.

23. Zeidan F, Martucci KT, Kraft RA, McHaffie JG, Coghill RC. Neural correlates of mindfulness meditation-related anxiety relief. Soc Cogn Affect Neurosci. 2014 Jun;9(6):751–9. doi:10.1093/scan/nst041 PubMed PMID: 23615765; PubMed Central PMCID: PMC4040088.

24. Demierre Berberat P. The Benefits of Grounding Strategies in Emotion and Arousal Regulation. MHRIJ. 2023 Dec 21;7(2):1–6. doi:10.23880/mhrij-16000233

25. Goldschen-Ohm MP. Benzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective. Biomolecules. 2022 Nov 30;12(12):1784. doi:10.3390/biom12121784 PubMed PMID: 36551212; PubMed Central PMCID: PMC9775625.

26. Sigel E, Ernst M. The Benzodiazepine Binding Sites of GABAA Receptors. Trends Pharmacol Sci. 2018 Jul;39(7):659–71. doi:10.1016/j.tips.2018.03.006 PubMed PMID: 29716746.

27. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11 Suppl 1(Suppl 1):11S-16S. doi:10.1111/j.1365-2125.1981.tb01833.x PubMed PMID: 6133528; PubMed Central PMCID: PMC1401650.

28. Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Teixeira J, Gonçalves AR. Effects of benzodiazepines administration on identification of facial expres-

sions of emotion: a meta-analysis. Psychopharmacology (Berl). 2020 Jan;237(1):1–9. doi:10.1007/s00213-019-05393-y PubMed PMID: 31740993.

29. Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, Schumacher M, Neumann ID. Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? Mol Psychiatry. 2022 Jul;27(7):2918–26. doi:10.1038/s41380-022-01561-3 PubMed PMID: 35444254.

30. Furukawa T, Nikaido Y, Shimoyama S, Masuyama N, Notoya A, Ueno S. Impaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice. Front Aging Neurosci. 2021;13:777404. doi:10.3389/fnagi.2021.777404 PubMed PMID: 34899279; PubMed Central PMCID: PMC8664496.

31. Bäckström T, Turkmen S, Das R, Doverskog M, Blackburn TP. The GABA system, a new target for medications against cognitive impairment-Associated with neuroactive steroids. J Intern Med. 2023 Sep;294(3):281–94. doi:10.1111/joim.13705 PubMed PMID: 37518841.

32. Vom Hofe I, Stricker BH, Vernooij MW, Ikram MK, Ikram MA, Wolters FJ. Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study. BMC Med. 2024 Jul 2;22(1):266. doi:10.1186/s12916-024-03437-5 PubMed PMID: 38951846; PubMed Central PMCID: PMC11218055.

33. Bustos SG, Maldonado H, Molina VA. Disruptive effect of midazolam on fear memory reconsolidation: decisive influence of reactivation time span and memory age. Neuropsychopharmacology. 2009 Jan;34(2):446–57. doi:10.1038/npp.2008.75 PubMed PMID: 18509330.

34. Hart G, Panayi MC, Harris JA, Westbrook RF. Benzodiazepine treatment can impair or spare extinction, depending on when it is given. Behav Res Ther. 2014 May;56:22–9. doi:10.1016/j.brat.2014.02.004 PubMed PMID: 24755207.

35. Guina J, Rossetter SR, DeRHODES BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015 Jul;21(4):281–303. doi:10.1097/PRA.0000000000000091 PubMed PMID: 26164054.

36. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Archives of Clinical Neuropsychology. 2004 Apr 1;19(3):437–54. doi:10.1016/S0887-6177(03)00096-9

37. Nishida M, Pearsall J, Buckner RL, Walker MP. REM sleep, prefrontal theta, and the consolidation of human emotional memory. Cereb Cortex. 2009 May;19(5):1158–66. doi:10.1093/cercor/bhn155 PubMed PMID: 18832332; PubMed Central PMCID: PMC2665156.

38. Boudreau P, Yeh WH, Dumont GA, Boivin DB. Circadian variation of heart rate variability across sleep stages. Sleep. 2013 Dec 1;36(12):1919–28. doi:10.5665/sleep.3230 PubMed PMID: 24293767; PubMed Central PMCID: PMC3825442.

39. Scarpelli S, Bartolacci C, D'Atri A, Gorgoni M, De Gennaro L. The Functional Role of Dreaming in Emotional Processes. Front Psychol. 2019;10:459. doi:10.3389/fpsyg.2019.00459 PubMed PMID: 30930809; PubMed Central PMCID: PMC6428732.

40. Muñoz-Torres Z, Velasco F, Velasco AL, Del Río-Portilla Y, Corsi-Cabrera M. Electrical activity of the human amygdala during all-night sleep and wakefulness. Clin Neurophysiol. 2018 Oct;129(10):2118–26. doi:10.1016/j.clinph.2018.07.010 PubMed PMID: 30103160.

41. Mendelsohn AR, Larrick JW. Sleep facilitates clearance of metabolites from the brain: glymphatic function in aging and neurodegenerative diseases. Rejuvenation Res. 2013 Dec;16(6):518–23. doi:10.1089/rej.2013.1530 PubMed PMID: 24199995.

42. Mohammadi M, Manaheji H, Maghsoudi N, Danyali S, Baniasadi M, Zaringhalam J. Microglia dependent BDNF and proBDNF can impair spatial memory performance during persistent inflammatory pain. Behav Brain Res. 2020 Jul 15;390:112683. doi:10.1016/j.bbr.2020.112683 PubMed PMID: 32442548.

43. Schaafsma W, Basterra LB, Jacobs S, Brouwer N, Meerlo P, Schaafsma A, Boddeke EWGM, Eggen BJL. Maternal inflammation induces immune activation of fetal microglia and leads to disrupted microglia immune responses, behavior, and learning performance in adulthood. Neurobiol Dis. 2017 Oct;106:291–300. doi:10.1016/j.nbd.2017.07.017 PubMed PMID: 28751257.

44. Giordano KR, Green TRF, Opp MR, Rowe RK. Microglial depletion and repopulation differentially modulate sleep and inflammation in a mouse model of traumatic brain injury. Neurobiol Sleep Circadian Rhythms. 2025 May;18(Suppl):100115. doi:10.1016/j.nbscr.2025.100115 PubMed PMID: 40703574; PubMed Central PMCID: PMC12282821.

45. Ni RJ, Yuan WJ, Wang YY, Yang X, Wei JX, Zhao LS, Wang Q, Tang XD, Ma XH. Microglia-mediated inflammation and synaptic pruning contribute to sleep deprivation-induced mania in a sex-specific manner. Transl Psychiatry. 2025 Aug 15;15(1):285. doi:10.1038/s41398-025-03525-x PubMed PMID: 40817224; PubMed Central PMCID: PMC12356969.

46. de Mendonça FMR, de Mendonça GPRR, Souza LC, Galvão LP, Paiva HS, de Azevedo Marques Périco C, Torales J, Ventriglio A, Castaldelli-Maia JM, Sousa Martins Silva A. Benzodiazepines and Sleep Architecture: A Systematic Review. CNS Neurol Disord Drug Targets. 2023;22(2):172–9. doi:10.2174/1871527320666210618103344 PubMed PMID: 34145997.

47. Guina J, Merrill B. Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives. J Clin Med. 2018 Jan 30;7(2):17. doi:10.3390/jcm7020017 PubMed PMID: 29385731; PubMed Central PMCID: PMC5852433.

48. Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. Am J Psychiatry. 2020 Jun 1;177(6):497–505. doi:10.1176/appi.ajp.2019.19030315 PubMed PMID: 32252539.

49. Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf. 2011 Feb 1;34(2):125–56. doi:10.2165/11539050-000000000-00000 PubMed PMID: 21247221.

50. Xu KY, Hartz SM, Borodovsky JT, Bierut LJ, Grucza RA. Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999-2015. JAMA Netw Open. 2020 Dec 9;3(12):e2028557. doi:10.1001/jamanetworkopen.2020.28557

51. Jehle J, Ficker E, Wan X, Deschenes I, Kisselbach J, Wiedmann F, Staudacher I, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol. 2013 Mar;168(5):1215–29. doi:10.1111/bph.12002 PubMed PMID: 23061993; PubMed Central PMCID: PMC3594678.

52. Gatti RC, Burke PR, Otuyama LJ, Almeida DR, Tufik S, Poyares D. Effects of Zolpidem CR on Sleep and Nocturnal Ventilation in Patients with Heart Failure. Sleep. 2016 Aug 1;39(8):1501–5. doi:10.5665/sleep.6006 PubMed PMID: 27166233; PubMed Central PMCID: PMC4945308.

53. Chen *Tien-Yu, Shen JY, Chung CH, Chien WC. THE USE OF ZOLPIDEM AND THE RISK OF ARRHYTHMIA: INSIGHTS FROM A NATIONAL SURVEY. Int J Neuropsychopharmacol. 2025 Feb 12;28(Suppl 1):i246. doi:10.1093/ijnp/pyae059.432 PubMed PMID: null; PubMed Central PMCID: PMC11814824.

54. Hall-Flavin BPK Meghna P Mansukhani, Laura Suarez, Daniel. QTc Prolongation Secondary to Zolpidem Use. Psychiatrist.com [Internet]. 2020 Mar 19 [cited 2026 Mar 23]. Available from: https://www.psychiatrist.com/pcc/qtc-prolongation-secondary-to-zolpidem-use/

55. Campagnari S, Zamboni L, Fusina F, Casari R, Lugoboni F. Case Report: High doses of Zolpidem and QT interval lengthening: Is there a relationship? A case series. Front Psychiatry. 2022;13:1033061. doi:10.3389/fpsyt.2022.1033061 PubMed PMID: 36339861; PubMed Central PMCID: PMC9632434.

56. Hu X, Jong GP, Wang L, Lin MC, Gong SQ, Zhang XH, Lin JJ, Adeniran E, Liu YL, Chen HY, Yang B. Hypnotics Use Is Associated with Elevated Incident Atrial Fibrillation: A Propensity-Score Matched Analysis of Cohort Study. J Pers Med. 2022 Oct 4;12(10):1645. doi:10.3390/jpm12101645 PubMed PMID: 36294784; PubMed Central PMCID: PMC9605069.

57. Kim HB, Myung SK, Park YC, Park B. Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies. Int J Cancer. 2017 Feb 1;140(3):513–25. doi:10.1002/ijc.30443 PubMed PMID: 27667780.

58. Pottegård A, Friis S, Andersen M, Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2013 May;75(5):1356–64. doi:10.1111/bcp.12001 PubMed PMID: 23043261; PubMed Central PMCID: PMC3635606.

59. Zhang T, Yang X, Zhou J, Liu P, Wang H, Li A, Zhou Y. Benzodiazepine drug use and cancer risk: a dose-response meta analysis of prospective cohort studies. Oncotarget. 2017 Nov 24;8(60):102381–91. doi:10.18632/oncotarget.22057 PubMed PMID: 29254253; PubMed Central PMCID: PMC5731963.

60. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012 Feb 27;2(1):e000850. doi:10.1136/bmjopen-2012-000850 PubMed PMID: 22371848; PubMed Central PMCID: PMC3293137.

61. Iqbal U, Nguyen PA, Syed-Abdul S, Yang HC, Huang CW, Jian WS, Hsu MH, Yen Y, Li YC (Jack). Is Long-term Use of Benzodiazepine a Risk for Cancer? Medicine (Baltimore). 2015 Feb 13;94(6):e483. doi:10.1097/MD.0000000000000483 PubMed PMID: 25674736; PubMed Central PMCID: PMC4602739.

62. Zetsen SPG, Schellekens AFA, Paling EP, Kan CC, Kessels RPC. Cognitive Functioning in Long-Term Benzodiazepine Users. Eur Addict Res. 2022;28(5):377–81. doi:10.1159/000525988 PubMed PMID: 36041417.

63. Roncero C, Bravo-Grande JL, Andrés-Olivera P, Peña M, Treceño C, González-Pelaez P, Aguilar L, Remón-Gallo D, González-Sánchez A. Benzodiazepine Misuse Among Health Care Workers: The Effect of Sleep Disorders on Work Performance. J Clin Med. 2025 Jun 16;14(12):4266. doi:10.3390/jcm14124266 PubMed PMID: 40566012; PubMed Central PMCID: PMC12194565.

64. Garbarino S, Lanteri P, Bragazzi NL, Gualerzi G, Riccò M. Occupational Injuries and Use of Benzodiazepines: A Systematic Review and Metanalysis. Front Hum Neurosci. 2021;15:629719. doi:10.3389/fnhum.2021.629719 PubMed PMID: 34054447; PubMed Central PMCID: PMC8155305.

65. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004 Sep;3(5):485–93. doi:10.1517/14740338.3.5.485 PubMed PMID: 15335303.

66. Chandramouleeshwaran S, Khan WU, Inglis F, Rajji TK. Impact of psychotropic medications on cognition among older adults: a systematic review. Int Psychogeriatr. 2024 Dec;36(12):1110–27. doi:10.1017/S1041610223000844 PubMed PMID: 37860872.

67. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician. 1998 Apr;44:799–808. PubMed PMID: 9585853; PubMed Central PMCID: PMC2277821.

68. Mathieu C, Joly P, Jacqmin-Gadda H, Wanneveich M, Bégaud B, Pariente A. Patterns of Benzodiazepine Use and Excess Risk of All-Cause Mortality in the Elderly: A Nationwide Cohort Study. Drug Saf. 2021 Jan;44(1):53–62. doi:10.1007/s40264-020-00992-7 PubMed PMID: 33125663.

69. Davies SJ, Rudoler D, de Oliveira C, Huang A, Kurdyak P, Iaboni A. Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study. J Psychopharmacol. 2022 Apr;36(4):460–9. doi:10.1177/02698811211069096 PubMed PMID: 35102786; PubMed Central PMCID: PMC9066681.

70. Davenport, Liam. Medscape [Internet]. 2023 [cited 2025 Dec 20]. Intermittent Use of Benzodiazepines Is the Safest Option. Available from: https://www.medscape.com/viewarticle/997282

71. Sun CF, Pola AS, Su KP, Lin BY, Kablinger AS, Trestman RL. Benzodiazepine use for anxiety disorders is associated with increased long-term risk of mood and substance use disorders: A large-scale retrospective cohort study. Drug Alcohol Depend Rep. 2024 Sep;12:100270. doi:10.1016/j.dadr.2024.100270 PubMed PMID: 39247100; PubMed Central PMCID: PMC11380165.

72. Dodds TJ. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. Prim Care Companion CNS Disord. 2017 Mar 2;19(2). doi:10.4088/PCC.16r02037 PubMed PMID: 28257172.

73. Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev. 2012;49(5):703–15. doi:10.1682/jrrd.2011.09.0183 PubMed PMID: 23015581.

74. Guideline Development Panel for the Treatment of PTSD in Adults, American Psychological Association. Summary of the clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. Am Psychol. 2019;74(5):596–607. doi:10.1037/amp0000473 PubMed PMID: 31305099.

75. Campos B, Vinder V, Passos RBF, Coutinho ESF, Vieira NCP, Leal KB, Mendlowicz MV, Figueira I, Luz MP, Marques-Portela C, Vilete LMP, Berger W. To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD?

A systematic review and meta-analysis. J Psychopharmacol. 2022 Apr;36(4):449–59. doi:10.1177/02698811221080464 PubMed PMID: 35437077.

76. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry. 2014 Dec;48(12):1096–114. doi:10.1177/0004867414548902 PubMed PMID: 25183003.

77. Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. J Affect Disord. 1995 Dec 13;35(3):117–23. doi:10.1016/0165-0327(95)00053-4 PubMed PMID: 8749839.

78. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998 Sep 26;317(7162):839–43. doi:10.1136/bmj.317.7162.839 PubMed PMID: 9748174; PubMed Central PMCID: PMC31092.

79. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8(6):461–75. doi:10.1016/0890-6238(94)90029-9 PubMed PMID: 7881198.

80. Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012 Sep;161(3):448–51. doi:10.1016/j.jpeds.2012.03.003 PubMed PMID: 22504099.

81. Diaz L, Eiden C, Jouanjus E, Frauger E, Fouilhé N, Djezzar S, Gibaja V, Boucher A, Le Boisselier R, Libert F, Caous AS, Monzon E, Guerlais M, Daveluy A, Fauconneau B, Peyrière H. Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020. Therapie. 2023;78(6):647–57. doi:10.1016/j.therap.2023.02.002 PubMed PMID: 36918317.

82. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019 Jul 1;200:95–114. doi:10.1016/j.drugalcdep.2019.02.033 PubMed PMID: 31121495; PubMed Central PMCID: PMC6639084.

83. Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. J Clin Psychiatry. 2018 Oct 16;79(6):18m12174. doi:10.4088/JCP.18m12174 PubMed PMID: 30403446; PubMed Central PMCID: PMC10309967.

84. Brandt J, Leong C. Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research. Drugs R D. 2017 Dec;17(4):493–507. doi:10.1007/s40268-017-0207-7 PubMed PMID: 28865038; PubMed Central PMCID: PMC5694420.

85. Darke S, Ross J, Cohen J. The use of benzodiazepines among regular amphetamine users. Addiction. 1994 Dec;89(12):1683–90. doi:10.1111/j.1360-0443.1994.tb03769.x PubMed PMID: 7866252.

86. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012 Sep 1;125(1–2):8–18. doi:10.1016/j.drugalcdep.2012.07.004 PubMed PMID: 22857878; PubMed Central PMCID: PMC3454351.

87. Brunner E, Chen CYA, Klein T, Maust D, Mazer-Amirshahi M, Mecca M, Najera D, Ogbonna C, Rajneesh KF, Roll E, Sanders AE, Snodgrass B, VandenBerg A, Wright T, Boyle M, Devoto A, Framnes-DeBoer S, Kleykamp B, Norrington J, Lindsay D, Clinical Guideline Committee (CGC) Members, ASAM Staff and Contractors. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. J Gen Intern Med. 2025 Sep;40(12):2814–59. doi:10.1007/s11606-025-09499-2 PubMed PMID: 40526204; PubMed Central PMCID: PMC12463801.

88. Guina J, Merrill B. Benzodiazepines II: Waking Up on Sedatives: Providing Optimal Care When Inheriting Benzodiazepine Prescriptions in Transfer Patients. J Clin Med. 2018 Jan 30;7(2):20. doi:10.3390/jcm7020020 PubMed PMID: 29385766; PubMed Central PMCID: PMC5852436.

89. Krüger C, Lindberg MH, Burmester S, Franck J, Westman J. Experiences of long-term benzodiazepine use and addiction amid changes in guidelines for the prescription of narcotic drugs: a qualitative study. BMC Public Health. 2025 Aug 5;25(1):2652. doi:10.1186/s12889-025-23920-9 PubMed PMID: 40764568; PubMed Central PMCID: PMC12326687.

90. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283–306. doi:10.1159/000506868 PubMed PMID: 32259826.

91. Palma E, Roseti C, Maiolino F, Fucile S, Martinello K, Mazzuferi M, Aronica E, Manfredi M, Esposito V, Cantore G, Miledi R, Simonato M, Eusebi F. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) "phasic" receptors. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20944–8. doi:10.1073/pnas.0710522105 PubMed PMID: 18083839; PubMed Central PMCID: PMC2409246.

92. Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481. doi:10.1002/14651858.CD011481.pub2 PubMed PMID: 29543325; PubMed Central PMCID: PMC6513394.

93. Alzghoul H, Al-Said MI, Obeidat O, Al-Ani H, Tarawneh M, Meadows R, Youness H, Reddy R, Al-Jafari M, Alzghoul BN, Khan A. Effectiveness of Gabapentin as a Benzodiaze-

pine-Sparing Agent in Alcohol Withdrawal Syndrome. Medicina (Kaunas). 2024 Jun 19;60(6):1004. doi:10.3390/medicina60061004 PubMed PMID: 38929621; PubMed Central PMCID: PMC11205746.

94. Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O. Review: Adjunctive pharmacologic approaches for benzodiazepine tapers. Drug Alcohol Depend. 2018 Aug 1;189:96–107. doi:10.1016/j.drugalcdep.2018.04.028 PubMed PMID: 29906718.

95. Croissant B, Grosshans M, Diehl A, Mann K. Oxcarbazepine in rapid benzodiazepine detoxification. Am J Drug Alcohol Abuse. 2008;34(5):534–40. doi:10.1080/00952990802149021 PubMed PMID: 18821451.

96. Mayoral V, Galvez R, Ferrándiz M, Miguéns Vázquez X, Cordero-García C, Alcántara Montero A, Pérez C, Pérez-Páramo M. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. Front Pain Res (Lausanne). 2024;5:1513597. doi:10.3389/fpain.2024.1513597 PubMed PMID: 39839199; PubMed Central PMCID: PMC11747324.

97. Burek GA, Waite MR, Heslin K, Liewen AK, Yaqub TM, Larsen SE. Low-dose clonidine in veterans with Posttraumatic stress disorder. J Psychiatr Res. 2021 May;137:480–5. doi:10.1016/j.jpsychires.2021.03.008 PubMed PMID: 33798975.

98. Mori H, Ochi S, Hashida H, Iga JI, Ueno SI. Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review. Clin Psychopharmacol Neurosci. 2025 Aug 31;23(3):520–5. doi:10.9758/cpn.24.1263 PubMed PMID: 40660699; PubMed Central PMCID: PMC12264677.

99. Bange JS, Melvin KE. Clonidine Use for the Treatment of Nightmares in Posttraumatic Stress Disorder. Case Rep Psychiatry. 2022;2022:5251406. doi:10.1155/2022/5251406 PubMed PMID: 35083090; PubMed Central PMCID: PMC8786541.

100. Jagtiani A, Gandhi R, Banga A, Blacker J, Joshi R, Bollu B, Kashyap R. Alpha-2 Agonists in Children and Adolescents With Post-traumatic Stress Disorder: A Systematic Review. Cureus. 2024 Jan;16(1):e53009. doi:10.7759/cureus.53009 PubMed PMID: 38410304; PubMed Central PMCID: PMC10895561.

101. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014 Feb;53(2):153–73. doi:10.1016/j.jaac.2013.11.009 PubMed PMID: 24472251.

102. Fernando ABP, Economidou D, Theobald DE, Zou MF, Newman AH, Spoelder M, Caprioli D, Moreno M, Hipólito L, Aspinall AT, Robbins TW, Dalley JW. Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopa-

minergic and noradrenergic receptor agonists. Psychopharmacology (Berl). 2012 Jan;219(2):341–52. doi:10.1007/s00213-011-2408-z PubMed PMID: 21761147; PubMed Central PMCID: PMC3249163.

103. Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–76. doi:10.2147/DDDT.S89485 PubMed PMID: 26834458; PubMed Central PMCID: PMC4716733.

104. Hasnain M, Vieweg WVR, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012 Jul;124(4):154–67. doi:10.3810/pgm.2012.07.2577 PubMed PMID: 22913904.

105. Khan N, Orange R. A Clinical Re-Audit (Cycle 1) on the Monitoring and Management of Antipsychotic-Induced Hyperprolactinaemia. BJPsych Open. 2025 Jun 20;11(Suppl 1):S251. doi:10.1192/bjo.2025.10620 PubMed PMID: null; PubMed Central PMCID: PMC12260709.

106. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Rüther E. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004 Jul;174(3):421–9. doi:10.1007/s00213-003-1759-5 PubMed PMID: 15029469.

107. Monti JM, Torterolo P, Pandi Perumal SR. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Med Rev. 2017 Jun;33:51–7. doi:10.1016/j.smrv.2016.05.002 PubMed PMID: 27321864.

108. Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. Can J Psychiatry. 2018 Jan 1;63(11):706743718777392. doi:10.1177/0706743718777392 PubMed PMID: 29758999; PubMed Central PMCID: PMC6299187.

109. Hwang ES, Song SB. Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment. Biomolecules. 2020 Apr 29;10(5):687. doi:10.3390/biom10050687 PubMed PMID: 32365524; PubMed Central PMCID: PMC7277745.

110. Baba Y, Inagaki S, Nakagawa S, Kaneko T, Kobayashi M, Takihara T. Effects of l-Theanine on Cognitive Function in Middle-Aged and Older Subjects: A Randomized Placebo-Controlled Study. J Med Food. 2021 Apr;24(4):333–41. doi:10.1089/jmf.2020.4803 PubMed PMID: 33751906; PubMed Central PMCID: PMC8080935.

111. Raad S, Wilkerson M, Jones KR, Orr WC. The effect of baclofen on objective and subjective sleep measures in a model of transient insomnia. Sleep Med. 2020 Aug;72:130–4. doi:10.1016/j.sleep.2020.03.028 PubMed PMID: 32615462.

112. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, Double-Blind, Placebo-Controlled Study of Clonidine in Restless Legs Syndrome. Sleep. 1996 Jan;19(1):52–8. doi:10.1093/sleep/19.1.52 PubMed PMID: 8650464.

113. Liu D, Hallt E, Platz A, Humblet A, Lassig-Smith M, Stuart J, Fourie C, Livermore A, McConnochie BY, Starr T, Herbst K, Woods CA, Pincus JM, Reade MC. Low-dose clonidine infusion to improve sleep in postoperative patients in the high-dependency unit. A randomised placebo-controlled single-centre trial. Intensive Care Med. 2024 Nov;50(11):1873–83. doi:10.1007/s00134-024-07619-w PubMed PMID: 39311905; PubMed Central PMCID: PMC11541301.

114. Kishi T, Ikuta T, Citrome L, Sakuma K, Hatano M, Hamanaka S, Nishii Y, Iwata N. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025 Jun 24;15(1):211. doi:10.1038/s41398-025-03439-8 PubMed PMID: 40555730; PubMed Central PMCID: PMC12187915.

115. Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. Sleep Med Rev. 2021 Dec;60:101556. doi:10.1016/j.smrv.2021.101556 PubMed PMID: 34607184; PubMed Central PMCID: PMC8651630.